NCT05278845View on ClinicalTrials.gov

Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 12, 2022

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
Food-drug Interaction
Interventions
DRUG

SLC-391

SLC-391 is an AXL inhibitor

Trial Locations (1)

G1P 0A2

Syneos Health Clinique Inc. (Quebec), Québec

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

SignalChem Lifesciences Corporation

INDUSTRY

NCT05278845 - Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter